公开(公告)号：US20230339882A1

公开(公告)日：2023-10-26

申请号：US18016144

申请日：2021-07-22

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Hao WU ,  Wenmao WU ,  Ling LI ,  Zhan ZHANG ,  Feng WANG ,  Ding YUAN ,  Yunfei WU ,  Qiang CHEN ,  Han HAN ,  Jing GUO ,  Hong LAN ,  Lieming DING ,  Jiabing WANG

IPC: C07D401/04 ,  A61P35/00 ,  C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D491/107 ,  C07D471/10 ,  C07D513/10 ,  C07D498/10

CPC classification number: C07D401/04 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/10 ,  C07D491/107 ,  C07D498/10 ,  C07D513/10

Abstract: A compound (as represented by formula I) serving as an Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor, as well as a pharmaceutical composition thereof, a preparation method therefor, and a use in treating an SHP2 mediation diseases. The compounds of formula I exerts an effect by means of participating in the regulation of multiple processes such as cell proliferation, apoptosis, migration, and angiogenesis.

公开(公告)号：US20230321100A1

公开(公告)日：2023-10-12

申请号：US18044049

申请日：2021-09-06

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Hao WU ,  Xiaofeng YANG ,  Qisheng LIU ,  Han HAN ,  Jinhua LI ,  Yang LI ,  Feng JIANG ,  Cuiwen KUANG ,  Hongfeng XIA ,  Hongbo ZHANG ,  Hong LAN ,  Jiabing WANG ,  Lieming DING

IPC: A61K31/513 ,  A61K39/395 ,  C07D403/04 ,  C07D401/14 ,  C07D403/14

CPC classification number: A61K31/513 ,  A61K39/3955 ,  C07D403/04 ,  C07D401/14 ,  C07D403/14

Abstract: The present invention relates to a novel compound, which has cancer therapeutic activity. The present invention also relates to a preparation method for the compound and a pharmaceutical composition comprising the compound.

公开(公告)号：US20230219956A1

公开(公告)日：2023-07-13

申请号：US17605268

申请日：2020-04-20

Applicant: BETTA PHARMACEUTICALS CO.,LTD

Inventor： Hao WU ,  Yuan LU ,  Jun YU ,  Xiao ZHOU ,  Boyan LI ,  Jiangqi HE ,  Shuibiao FU ,  Rongwen YANG ,  Yabin LI ,  Chao WANG ,  Jiabing WANG ,  Hong LAN ,  Lieming DING

IPC: C07D471/10 ,  C07D519/00 ,  C07D487/10 ,  C07D401/14 ,  C07D451/04 ,  A61P35/00

CPC classification number: C07D471/10 ,  C07D519/00 ,  C07D487/10 ,  C07D401/14 ,  C07D451/04 ,  A61P35/00

Abstract: The present invention relates to a novel compound, which has cancer therapeutic activity. The present invention also relates to a preparation method for the compound and a pharmaceutical composition containing the compound. (I)

公开(公告)号：US20210261552A1

公开(公告)日：2021-08-26

申请号：US16973335

申请日：2019-06-06

Applicant: Betta Pharmaceuticals Co., LTD

Inventor： Hao WU ,  Wei GU ,  Xiaojing TANG ,  Wei WANG ,  Bo ZHAN ,  Dongjie FENG ,  Yongxin KE ,  Zhongyan CHEN ,  Yifei SHEN ,  Wenmao WU ,  Xintao ZHAO ,  Hong LAN ,  Jiabing WANG ,  Lieming DING

IPC: C07D487/04 ,  A61P35/00 ,  C07D401/04 ,  C07D417/04 ,  C07D491/20 ,  C07D403/14 ,  C07D487/20 ,  C07D519/00 ,  C07D513/04

Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.